Document:

EXHIBIT 10.9

                              ASSIGNMENT AGREEMENT

     THIS  AGREEMENT  is  made  and entered into as of this 25th day of May 2005
("Effective  Date")  by  and  between  PATHOGENICS, INC., a Delaware corporation
having offices at 99 Derby Street, Suite 200, Hingham, MA 02043 ("PATHOGENICS"),
and  FIRST  COVENTRY  CORPORATION,  a  Delaware corporation having offices at 99
Derby  Street,  Suite  200,  Hingham,  MA  02043  ("FIRST  COVENTRY").

     WHEREAS,  PATHOGENICS  is  party  to  a  certain  License  Agreement  for
Chloroquine  patents  and  patent  applications  ("CQ')  entered on May 25, 2005
between PATHOGENICS (as exclusive, worldwide Licensee) and Alpha Research Group,
LLC  and  Jodi  A.  Nelson  (collectively,  the  Licensors),  a copy of which is
attached  hereto  as  Exhibit  A.

     WHEREAS,  on  May  25,  2005 the PATHOGENICS board of directors resolved by
unanimous  written  consent  to  assign  to  FIRST COVENTRY all of PATHOGENICS's
rights  and  obligations  under the aforementioned License Agreement in exchange
for  100%  of  the  stock  of  FIRST COVENTRY thereby making it its wholly owned
subsidiary,  a  copy  of  which  is  attached  hereto  as  Exhibit  B.

     WHEREAS,  FIRST  COVENTRY desires to acquire, and PATHOGENICS is willing to
assign  to  FIRST COVENTRY all of PATHOGENICS's rights and obligations under the
aforementioned  License  Agreement.

     ACCORDINGLY,  for  good  and  valuable  consideration  described  below

     1.     PATHOGENICS  hereby  assigns,  transfers,  conveys  and relinquishes
exclusively  to  FIRST  COVENTRY,  its  lawful  successors  and  assigns, all of
PATHOGENICS's  rights  and obligations under the May 25, 2005 License Agreement.

     2.     FIRST  COVENTRY  assumes,  and  agrees  to  pay  and  perform,  all
unperformed  obligations  of  PATHOGENICS  under  the  License Agreement.  FIRST
COVENTRY  agrees  that by executing and delivering this Agreement FIRST COVENTRY
shall  become  a party to the License Agreement and agrees to be bound by all of
the  terms  and  provisions  of  the  License  Agreement.

     3.     In  furtherance  of  this Agreement, PATHOGENICS hereby acknowledges
that,  from  the  Effective Date forward, FIRST COVENTRY has succeeded to all of
PATHOGENICS's  rights,  obligations,  title,  and  standing  in  relation to the
License Agreement, to institute and prosecute all suits and proceedings, to take
all  actions  that FIRST COVENTRY, in its sole discretion, may deem necessary or
proper  to  collect,  assert,  or enforce any claim, right, or title of any kind
under  the  License  Agreement,  whether  arising  before or after the Effective
Date,  to  defend and compromise any and all such actions, suits, or proceedings
relating to such transferred and assigned rights, title, interest, and benefits,
and  to  do all other such acts and things in relation thereto as FIRST COVENTRY
in  its  sole  discretion  deems  advisable.

<PAGE>

     6.     PATHOGENICS  represents  and  warrants  that,  to  the  best  of
PATHOGENICS's  knowledge,  upon  consummation  of this Agreement, FIRST COVENTRY
shall have good and marketable title to the License Agreement, free and clear of
any  and  all  liens,  mortgages,  encumbrances,  pledges,  security  interests,
licenses,  or  charges  of  any  nature  whatsoever.

     7.     This  Agreement  shall inure to the benefit of, and be binding upon,
the  parties  hereto  together  with  their  respective  legal  representatives,
successors  and  assigns.

     8.     This Agreement shall be governed by and construed in accordance with
the laws of the Commonwealth of Massachusetts (excluding conflicts of law rules)
and  of  the  United  States  of  America.

     9.     This  Agreement  merges and supersedes all prior and contemporaneous
agreements, assurances, representations, and communications between or among the
parties  hereto  concerning  the  matters  set  forth  herein.

     10.     If  a  dispute  arises  out  of  or relates to this Agreement, or a
breach  thereof,  and  if the dispute cannot be settled through negotiation, the
parties  agree  to  first  try  in good faith to settle the dispute by mediation
administered  by  the  American  Arbitration  Association  under  its Commercial
Mediation  Rules  before  resorting  to  arbitration,  litigation, or some other
dispute  resolution  procedure.

     11.     Any  claim  or  controversy  arising  out  of  or  relating to this
Agreement, or the breach thereof, that cannot be settled through mediation shall
be  settled  by arbitration administered by the American Arbitration Association
under its Commercial Arbitration Rules, and judgment o the award rendered by the
arbitrator  may  be  entered  in  any  court  having  jurisdiction  thereof.

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement the day
and  year  first  written  above.

PATHOGENICS,  INC.                         FIRST  COVENTRY  CORPORATION

By: /s/ Frederic P. Zotos                  By: /s/ Frederic P. Zotos
    ---------------------------                ---------------------------------
Name:  Frederic  P.  Zotos,  Esq.          Name:  Frederic  P. Zotos,  Esq.
Title: President  &  CEO                   Title: President  & CEO
Date:                                      Date:
    ---------------------------                ---------------------------------

<PAGE>

                                    EXHIBIT A

                         May 25, 2005 License Agreement
                                     between
                  Alpha Research Group, LLC and Jodi A. Nelson
                                       and
                                Pathogenics, Inc.

<PAGE>

                                    EXHIBIT B

       May 25, 2005 Statement of Unanimous Consent of Board of Directors of
      Pathogenics, Inc., Resolution to Acquire100% of Stock of First Coventry
                                   Corporation

<PAGE>EXHIBIT 10.10

                              CONSULTANCY AGREEMENT
                              ---------------------

     CONSULTANCY  AGREEMENT  (the  "Agreement")  dated  as  of May 25, 2005 (the
"Effective Date"), by and between Pathogenics, Inc., a Delaware corporation (the
"Corporation"),  having  a  place  of  business  at  99 Derby Street, Suite 200,
Hingham, MA 02043, and Jodi A. Nelson (the "Consultant"), an individual residing
at  1717  Valentia  Street,  Denver,  CO  80220.

     WHEREAS,  the  Corporation  desires  that  it  be  able  to  call  upon the
experience  and  knowledge  of  Consultant  for consultation services and advice
concerning  the use of any therapeutic use or formulation of Chloroquine and any
of  its  derivatives  or  analogs  and  the  technical  evaluation of commercial
applications of such technology; and,

     WHEREAS,  Consultant  is willing to render such services to the Corporation
on the terms and conditions hereinafter set forth in this Agreement;

     NOW,  THEREFORE,  in  consideration  of  the  promises and mutual covenants
contained  herein  and  for  other  good and valuable consideration, the parties
hereto agree as follows:

     1.     Term  and  Termination  of  Agreement.  Commencing  on the Effective
            -------------------------------------
Date,  Consultant  shall be retained by the Corporation on a monthly basis for a
period  of  one (1) year, which shall be renewable upon written agreement of the
parties for additional one-year periods.  The initial term and any extensions or
renewals  thereof shall constitute the "Consulting Term."  This Agreement may be
terminated  by  either  party  at  any  time  upon one (1) month's prior written
notice.

     2.     Position and Responsibilities.  Consultant hereby agrees to serve as
            -----------------------------
a  consultant  to  the Corporation and to render such advice and services to the
Corporation  as may be reasonably required by the Corporation including, without
limitation,  advising  the  Corporation  with  respect  to  the direction of the
Corporation's  research  and  product  development  and  business  development
activities.  During  the  Consulting  Term,  Consultant shall report directly to
Frederic  P.  Zotos,  President  of  the  Corporation.

<PAGE>

     3.     Compensation.  The  Corporation  shall  pay  Consultant  a  monthly
            ------------
retainer  of  three-thousand  dollars  ($3,000/month) per month for Consultant's
first  forty  (40)  hours  of  billable  work  each month, and an hourly rate of
seventy-five  dollars  per  hour ($75/hr.) for each hour thereafter.  Consultant
shall  not exceed forty hours of billable work per month without first providing
the  Corporation  with a written estimate of the expected excess hours, and then
obtaining  written  pre-authorization  from  the  Corporation.  Consultant shall
provide  the  Corporation  with  a  monthly  invoice  documenting  Consultant's
activities  and  billable  time,  and  Corporation  shall  pay this invoice upon
receipt (except as indicated herein below) if the amount is not in dispute.  The
Corporation  shall  pay the Consultant the first month's retainer of $3,000 upon
receiving  the  Consultant's  executed  copy of this Agreement.  Notwithstanding
anything  to the contrary above, payment of the invoices following the execution
of  this  Agreement  shall be deferred and accrued by the Corporation until such
time  as the Corporation's stock registration statement is declared effective by
the  US  Securities and Exchange Commission, whereupon the Corporation shall pay
all  the  deferred and accrued invoices, and shall cease to defer and accrue any
future  invoices.

     4.     Expenses.  Consultant  shall  be  reimbursed  in accordance with the
            --------
policies  of  the Corporation for necessary and reasonable pre-approved business
expenses  incurred  by  Consultant  in  connection with their performance of his
duties  hereunder.  Consultant  shall  provide  the  Corporation with an invoice
documenting  Consultant's  reimbursable expenses, and Corporation shall pay this
invoice  within  thirty  (30)  days  of receipt if the amount is not in dispute.

     5.     Confidentiality.  Consultant  recognizes  and  acknowledges that, in
            ---------------
the  course  of  his  duties, Consultant may receive confidential or proprietary
information  owned  by  the  Corporation  or  other  third parties with whom the
Corporation  has  an obligation of confidentiality.  Therefore, during and after
the  Consulting Term, Consultant agrees to keep confidential and not disclose or
use  (except  in connection with the fulfillment of his consulting duties to the
Corporation  under  this  Agreement) all confidential or proprietary information
owned  by  or  receive  by  or  on  behalf  of  the  Corporation.  "Confidential
Information"  shall  include,  but  shall  not  be  limited  to, confidential or
proprietary scientific or technical information customers, development programs,
costs,  marketing,  trading, investment, sales activities, promotion, credit and
financial  data,  manufacturing  processes,  financing  methods,  plans  or  the
business  and  affairs  of  the  Corporation  generally, or of any subsidiary or
affiliate  of  the  Corporation.  "Confidential  Information" shall not include,
however,  information  in the public domain, information disclosed to Consultant
by  a  third party entitled to disclose it without obligation of confidentiality
or  information  already  known  to  Consultant  prior  to  its  receipt.

<PAGE>

     6.     Non-Solicitation.  During  the  Consulting  Term and for a period of
            ----------------
one year thereafter, Consultant shall not directly or indirectly employ, solicit
for  employment  or  advise or recommend to any other person that they employ or
solicit  for  employment  any  person  whom  he  knows  to be an employee of the
Corporation  or  any  parent,  subsidiary  or  affiliate  of  the  Corporation.

     7.     Ownership  of  Work Product and Inventions.  In consideration of the
            ------------------------------------------
compensation  paid  to  the Consultant by the Corporation in paragraph 3 of this
Agreement, Consultant hereby assigns to the Corporation all his right, title and
interest  in all Consultant's work product and inventions, including any and all
data,  plans,  reports  and  recommendations,  as  well  as  any  inventions  or
improvements,  conceived  or  made  individually  or  jointly  with others while
performing  consulting  activities  under  this  Agreement, relating to any work
within  the  scope  of  this Agreement and/or relating to the business of and/or
resulting  from  Consultant's  services  upon  behalf  of the Corporation ("Work
Product  and  Inventions")  shall  be considered as work made for hire, made and
held  by  Consultant  in  a  fiduciary capacity for the exclusive benefit of the
Corporation.  Work  Product  and  Inventions  shall  be  the  sole and exclusive
property  of  the  Corporation  and  shall  not  be disclosed to any other party
without  the prior written approval of the Corporation and such Work Product and
Inventions  shall  be  considered  Confidential  subject  to  section  5  above.

Consultant  shall  promptly  and  disclose  fully  to  the  Corporation  or  its
designated  agent, but to no other person, any and all inventions, improvements,
formulas,  processes  and the like (also "Inventions"), arising while performing
consulting  activities  under this Agreement. When requested by the Corporation,
either  during  or  subsequent  to  the term of this Agreement, Consultant shall
assist the Corporation and its agents in the preparation, filing and prosecution
of  patent  applications,  covering  such  inventions, and in the enforcement or
defense  of  any  patent  which  may  issue  therefrom. Consultant shall assign,
transfer, and set over unto the Corporation his entire right, title and interest
in  and  to  any  and  all  Work  Product  and Inventions, as well as any patent
application(s)  relating to such Work Product and Inventions that arise from his
consulting  activities  for  the  Corporation  hereunder.  Consultant  agrees to
cooperate fully in the prosecution of any patent applications resulting from any
such  invention,  at  the  expense  of  the Corporation, which cooperation shall
include  executing  any necessary documents in connection therewith.  The filing
of  all  such  applications,  as  well as the issuance and maintenance of patent
therefrom,  shall  be  at  the  sole  discretion  of  the  Corporation.

     8.     Specific  Performance.  Consultant  acknowledges and agrees that the
            ---------------------
Corporation's  remedies  at  law  for a breach or threatened breach of an of the
provisions  of  paragraph 5 through 7 of this Agreement would be inadequate and,
in  recognition  of  this  fact,  Consultant agrees that, in the event of such a
breach or threatened breach, in addition to any remedies at law, the Corporation
shall  be  entitled  to  obtain  equitable  relief  in  the  form  of  specific
performance,  temporary  restraining order, temporary or permanent injunction or
any  equitable  remedy  which  may  then  be  available.

<PAGE>

     9.     Representation  of  Consultant:  Use  of  Name.  Consultant  hereby
            ----------------------------------------------
represents  that  his  current  principal  place(s)  of  employment has received
disclosure as to the duties required of Consultant under this Agreement and that
such  employer(s) consents fully to Consultant's execution of this Agreement and
the  obligations under this Agreement.  Consultant further represents that there
are  no  binding  agreements  to  which  he  is  a party or by which he is bound
forbidding  or  restricting  his  activities  herein.  In  addition,  Consultant
consents to the use of his name in various reports, brochures or other documents
produced  by  or  on  behalf of the Corporation, including any and all documents
filed  with  the  Securities  and  Exchange  Commission.

     10.     Consultant  Not an Employee.  The Corporation and Consultant hereby
             ---------------------------
acknowledge and agree that Consultant shall perform the services hereunder as an
independent  contractor  and  not as an employee of the Corporation.  Consultant
agrees  that  he  will file his own tax returns on the basis of his status as an
independent  contractor  for  the  reporting  of  all  income,  social security,
employment  and  other  taxes due and owing on the consideration received by him
under  this  Agreement and that he is responsible for the payment of such taxes.
Similarly,  Consultant shall not be entitled to benefits specifically associated
with  employment  status,  such  as medical, dental and life insurance, stock or
stock  options  of  the  Corporation  (except  as  specifically provided in this
Agreement)  and  shall  not  be  entitled  to  participate in any other employer
benefit  programs.  As  an  independent  contractor,  Consultant  acknowledges,
understands  and agrees that he is not, and shall not represent himself to third
parties  as  being,  the  agent or representative of the Corporation nor does he
have,  and  shall  not  represent  himself  to third parties as having, power or
authority  to  do or take any action for or on behalf of the Corporation, as its
agent,  representative  or  otherwise,  except as specifically set forth herein.
Consultant  agrees  to  defend, indemnify and hold the Corporation harmless from
any  and  all  claims  made  by  any  entity on account of an alleged failure by
Consultant  to  satisfy  any  tax  or  withholding  obligations.

     11.     Representation and Warranty.  Consultant represents and warrants to
             ---------------------------
the  Corporation  that  all  services  and advice offered to the Corporation are
provided  based  on best efforts and a good faith belief of the veracity of such
services  and  advice. Given such representations and warranties the Corporation
agrees  to not hold Consultant liable for any errors, omissions or consequential
damages  that may occur as a result of Consultant's services provided hereunder.

     12.     Limitation  of  Liability.  Corporation  acknowledges  that  it has
             -------------------------
substantial  knowledge,  experience and expertise with respect to the matters as
to  which Consultant will provide consulting services and that it is able to and
will  independently evaluate any advice rendered by Consultant to Corporation in
the  performance  of  its  duties hereunder.  Therefore, Corporation agrees that
neither  Consultant  nor  any  of  its  officers,  directors,  shareholders  or
affiliates  shall  have  any  liability  whatsoever  for  any advice rendered to
Corporation  under  this  Agreement.  Corporation's sole remedy for Consultant's
failure  to perform under the terms of this Agreement shall be to terminate this
Agreement  in  accordance  with  the  terms  of  Section  1  herein.

<PAGE>

     13.     Indemnification.  Corporation  shall  indemnify and hold Consultant
             ---------------
harmless  from  any  claim,  suit,  loss, liability damage or expense (including
attorney's  reasonable  fees)  arising  from  Consultant's  service  hereunder,
including  any losses arising from the use by Corporation of any advice given by
Consultant.  Consultant  shall  indemnify and hold Corporation harmless from any
losses  arising  from negligence or wrongful or intentionally willful misconduct
or  omissions  of  Consultant.

     14.     Consulting  for  Third  Parties.  The  Corporation  recognizes that
             -------------------------------
Consultant  may,  from time to time during the term of this Agreement and at his
sole  discretion,  provide  consulting  services  to  other parties.  Consultant
agrees  to notify the Corporation in such case and to provide information to the
Corporation as reasonably necessary to demonstrate that such consulting services
do  not  compete  with  the  business  of the Corporation.  The Corporation also
agrees  to permit Consultant to notify other parties with information about this
Agreement  as  reasonably necessary to demonstrate that such consulting services
do  not  compete  with  the  business  of  the  Corporation.

     15.     Miscellaneous,
             -------------

          (a)  Governing  Law  and  Dispute  Resolution. This Agreement shall be
               ----------------------------------------
     governed  by  and construed in accordance with the laws of the Commonwealth
     of  Massachusetts,  without  regard  to  principals  of  conflicts of laws.
     Subject  to  the  following,  for  purposes  of  this Agreement, each Party
     consents,  for itself and its Affiliates, to the jurisdiction of the courts
     of  the  state  of Illinois, county of Cook and the U.S. District Court for
     Illinois.

               i.  The  Corporation  and the Consultant (the "Parties") agree to
          attempt  initially  to  solve  all  claims, disputes, or controversies
          arising  under,  out  of,  or  in  connection  with  this Agreement (a
          "Dispute")  by  conducting good faith negotiations. Any Disputes which
          cannot  be  resolved  by  good  faith  negotiation  within twenty (20)
          Business  Days, shall be referred, by written notice from either Party
          to  the  other. The Parties shall negotiate in good faith to achieve a
          resolution of the Dispute referred to them within twenty (20) Business
          Days after such notice is received by the Party to whom the notice was
          sent.  If  the  Parties  are  unable  to  settle  the  Dispute between
          themselves  within  twenty (20) Business Days, they shall so report to
          the  Parties  in  writing.  The  Dispute  shall  then  be  referred to
          mediation as set forth in the following subsection (ii).

<PAGE>

               ii.  Upon  the  Parties  receiving  the  Parties' report that the
          Dispute  referred  to  them  pursuant  to  subsection (i) has not been
          resolved, the Dispute shall be referred to mediation by written notice
          from  either  Party  to  the  other.  The mediation shall be conducted
          pursuant  to  the  Rules of the Commercial Arbitration of the American
          Arbitration Association ("AAA") procedures. The place of the mediation
          shall  be in Chicago, IL. If the Parties have not reached a settlement
          within  twenty  (20)  Business  Days  of  the  date  of  the notice of
          mediation,  the  Dispute  shall be referred to arbitration pursuant to
          subsection (iii) below.

               iii.  If  after  the  procedures set forth in subsections (i) and
          (ii) above, the Dispute has not been resolved, a Party shall decide to
          institute  arbitration  proceedings,  it  shall give written notice to
          that  effect  to  the  other  Party.  The  Parties  shall refrain from
          instituting  the  arbitration  proceedings  for a period of sixty (60)
          days  following  such  notice.  During  such period, the Parties shall
          continue  to  make  good faith efforts to amicably resolve the dispute
          without  arbitration.  If  the  Parties  have not reached a settlement
          during that period the arbitration proceedings shall go forward and be
          governed  by  the AAA rules then in force. Each such arbitration shall
          be  conducted by a panel of three arbitrators: one arbitrator shall be
          appointed  by  each  of  Corporation  and  Consultant  and  the  third
          arbitrator,  who  shall  be  the  Chairman  of  the tribunal, shall be
          appointed  by  the  two  Party-appointed arbitrators. The place of the
          arbitration shall be in Chicago, IL.

               The  arbitrators  shall  have  the  authority  to  grant specific
          performance. Judgment upon the award so rendered may be entered in any
          court having jurisdiction or application may be made to such court for
          judicial  acceptance  of any award and an order of enforcement, as the
          case  may be. In no event shall a demand for arbitration be made after
          the  date when institution of a legal or equitable proceeding based on
          such claim, dispute or other matter in question would be barred by the
          applicable statute of limitations. Each Party shall bear its own costs
          and  expenses  incurred  in connection with any arbitration proceeding
          and  the  Parties  shall  equally  share the cost of the mediation and
          arbitration levied by the AAA.

               Any  mediation or arbitration proceeding entered into pursuant to
          this Section shall be conducted in the English language.

          (b)  Entire  Agreement. This Agreement, with the attached Statement of
               -----------------
     Work  and  Fees,  contains  the  entire  understanding  of the parties with
     respect  to  the  retention  of Consultant by the Corporation. There are no
     restrictions,  agreements,  promises,  warranties, covenants or undertaking
     between  the  parties  with respect to the subject matter herein other than
     those  expressly  set  forth  herein.  This  Agreement  may not be altered,
     modified  or  amended  except  by  written instrument signed by the parties
     hereto.

<PAGE>

          (c)  No Waiver. The failure of a party to insist upon strict adherence
               ---------
     to  any  term  of  this Agreement on any occasion shall not be considered a
     waiver of such party's rights or deprive such party of the right thereafter
     to  insist  upon  strict  adherence  to that term or any other term of this
     Agreement.

          (d)  Severability. In the event that any one or more of the provisions
               ------------
     of  this  Agreement shall be or become invalid, illegal or unenforceable in
     any  respect,  the  validity,  legality and enforceability of the remaining
     provisions of this Agreement shall not be affected thereby.

          (e)  Successor;  Binding  Agreement. This Agreement shall inure to the
               ------------------------------
     benefit  of  and  be  binding  upon the parties hereto and their respective
     heirs,  representatives,  successors and assigns. Consultant may not assign
     this Agreement without the prior written consent of the corporation.

          (f)  Counterpart;  Effectiveness.  This  Agreement  may  be  signed in
               ---------------------------
     counterparts,  each  of which shall be an original, with the same effect as
     if the signatures thereto and hereto were upon the same instrument.

          (g)  Survival  of Termination. Paragraph 5 (only for three years after
               ------------------------
     the  termination  of  this  Agreement),  6  (only  for  one  year after the
     termination  of  this  Agreement),  7,  8,  9,  10, 11, 12, 13 and 15 shall
     survive the termination of this Agreement.

<PAGE>

          IN  WITNESS WHEREOF, the undersigned have duly executed this Agreement
as  of  the  date  first  above  written.

                           PATHOGENICS,  INC.

                                     By /S/ Frederic P. Zotos
                                        --------------------------
                                        Frederic  P.  Zotos,  Esq.
                                        President  &  CEO

                           JODI  A.  NELSON.

                                     By /S/ Jodi A. Nelson
                                        --------------------------
                                        Jodi  A.  Nelson

<PAGE>

                            STATEMENT OF WORK & FEES
                            ------------------------

                                 Jodi A. Nelson
                                    May 2005

                               CONSULTING DUTIES:
                                -----------------

     Evaluate  the  therapeutic use or formulation of Chloroquine and any of its
derivatives  or  analogs and the technical evaluation of commercial applications
of  such  technology  by:

-    Assisting the Corporation's research and development of the technology;

-    Assisting the Corporation's regulatory approval process of the technology;

-    Identifying  and  drafting  a  detailed  technical  disclosure of any novel
     therapeutic  use  or  formulation  of  Chloroquine  and  any  of  its
     derivatives or analogs;

-    Evaluating the feasibility of the technical and commercial applications of
     the technology;

-    Assisting  the Corporation's efforts to obtain third-party grants and
     funding for developing the technology; and,

-    Identifying  any  potential  licensee's  of  the  technology.

                                      FEES:
                                      -----

-    $3,000 per month for first 40 hours, $75 per hour thereafter with first
     obtaining  written  authorization  from  the  Corporation,  to be paid upon
     receipt of itemized bill if amount is not in dispute

-    plus reasonable, pre-approved expenses.

     Notwithstanding anything to the contrary above:

-    First month's $3,000 to be paid upon delivery of executed Agreement;

-    Subsequent invoices shall be deferred and accrued until such time as the
     Corporation's  stock  registration  statement  is  declared  effective  by
     the  US Securities and Exchange Commission, whereupon the Corporation shall
     pay  all  the  deferred  and accrued invoices, and shall cease to defer and
     accrue any future invoices.

<PAGE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00087-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00087-of-00352.parquet"}]]